RenovoRx Inc

RNXT

Company Profile

  • Business description

    RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

  • Contact

    2570 West El Camino Real
    Suite 320
    Mountain ViewCA94040
    USA

    T: +1 650 284-4433

    https://www.renovorx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    17

Stocks News & Analysis

stocks

AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
stocks

The most popular ASX trades in FY26

A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.
stocks

Chart of the Week: The CBA chart you can’t ignore

Where value remains in Australian banks.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,018.1041.40-0.46%
CAC 408,374.1263.77-0.76%
DAX 4025,069.4585.96-0.34%
Dow JONES (US)52,218.586.06-0.01%
FTSE 10010,717.440.470.00%
HKSE25,210.81318.151.28%
NASDAQ25,690.90146.30-0.57%
Nikkei 22566,422.60307.000.46%
NZX 50 Index13,795.3132.130.23%
S&P 5007,498.9610.24-0.14%
S&P/ASX 2008,839.0038.60-0.43%
SSE Composite Index3,876.789.740.25%

Market Movers